68 results
Page 2 of 4
8-K
EX-99.1
qwz4i26fjf wly082w
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm
8-K
EX-99.1
xbsxna2nlb
22 Oct 20
Regulation FD Disclosure
1:14pm
8-K
EX-99.1
517 u7n608
19 Jun 20
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
8:06am
8-K
EX-99.1
7buk0q9nph iof7
17 Jun 20
Regulation FD Disclosure
1:11pm
8-K
EX-99.2
hy28crd0mt88v4
7 May 20
Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
8:10am
424B5
xsalm4qku 7k0d
7 Oct 19
Prospectus supplement for primary offering
9:35pm
424B5
y0p56r324wyvf
7 Oct 19
Prospectus supplement for primary offering
9:33pm
424B5
pln86ujg
3 Oct 19
Prospectus supplement for primary offering
4:11pm